PHR logo

Pharmena S.A. Stock Price

WSE:PHR Community·zł34.5m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 2 Fair Values set on narratives written by author

PHR Share Price Performance

zł3.10
-0.40 (-11.43%)
zł3.10
-0.40 (-11.43%)
Price zł3.10

PHR Community Narratives

There are no narratives available yet.

Trending Discussion

No trending discussion available.

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Adequate balance sheet with low risk.

3 Risks
0 Rewards

Pharmena S.A. Key Details

zł1.6m

Revenue

zł243.0k

Cost of Revenue

zł1.4m

Gross Profit

zł4.1m

Other Expenses

-zł2.8m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Aug 26, 2026
-0.25
84.86%
-172.02%
0%
View Full Analysis

About PHR

Founded
2002
Employees
7
CEO
Konrad Palka
WebsiteView website
www.pharmena.eu

Pharmena S.A. engages in the sale of dietary supplements in Poland and internationally. The company also develops 1-MNA (PHR-701 program), a medical device for use in difficult-to-heal wounds. In addition, it is involved in research and development of therapeutic applications of 1 MNA as an anti-inflammatory and anti-fibrotic drug; and research and development at pulmonary fibrosis, respiratory tract infections, including viral infections, COVID-19, inflammatory diseases, metabolic diseases and other therapeutic applications. The company was incorporated in 2002 and is based in Lódz, Poland. Pharmena S.A. is a subsidiary of Pelion S.A.

Recent PHR News & Updates

Recent updates

No updates